XEN1101, a novel, potent potassium channel modulator: Interim data from an ongoing, long-term, open-label extension of a Phase 2b study (X-TOLE) in adults with focal onset seizures (FOS)

被引：0
|
作者：
French, J. [1 ,2 ]
Porter, R. [3 ]
Perucca, E. [4 ,5 ]
Brodie, M. [6 ]
Rogawski, M. A. [7 ]
Harden, C. [8 ]
Qian, J. [8 ]
Rosenblut, C. Luzon [8 ]
Kenney, C. [8 ]
Beatch, G. N. [8 ]
机构：
[1] NYU, Grossman Sch Med, New York, NY USA
[2] NYU, NYU Langone Hlth, New York, NY USA
[3] Univ Penn, Philadelphia, PA USA
[4] Monash Univ, Melbourne, Vic, Australia
[5] Univ Melbourne, Austin Hlth, Heidelberg, Australia
[6] Univ Glasgow, Dept Med & Therapeut, Western Infirm, Glasgow, Scotland
[7] Univ Calif Davis, Sch Med, Sacramento, CA USA
[8] Xenon Pharmaceut Inc, Vancouver, BC, Canada
来源：
EPILEPSIA | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
631
引用
收藏
页码：184 / 184
页数：1
相关论文
共 29 条
  • [21] Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
    Gladman, Dafna
    Coates, Laura
    Mease, Philip
    van den Bosch, Filip
    Rychlewska-Hanczewska, Anna
    Tasset, Chantal
    Meuleners, Luc
    Trivedi, Mona
    Guo, Ying
    Besuyen, Robin
    Helliwell, Philip
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1066 - 1067
  • [22] Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
    Coates, Laura
    Mease, Philip
    Gladman, Dafna
    Van den Bosch, Filip
    Rychlewska-Hanczewska, Anna
    Tasset, Chantal
    Meuleners, Luc
    Trivedi, Mona
    Gao, Jingjing
    Besuyen, Robin
    Helliwell, Philip
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [23] LONG-TERM SAFETY AND TOLERABILITY OF ACORAMIDIS (AG10) IN SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: UPDATED ANALYSIS FROM AN ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY
    Masri, Ahmad
    Aras, Mandar
    Falk, Rodney H.
    Grogan, Martha
    Jacoby, Daniel
    Judge, Daniel P.
    Shah, Sanjiv Jayendra
    Witteles, Ronald
    Ji, Alan X.
    Wong, Paul W.
    Cao, Xiaofan
    Vanlandingham, Rebecca
    Katz, Leonid
    Sinha, Uma
    Fox, Jonathan C.
    Maurer, Mathew S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 227 - 227
  • [24] Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
    Craig, Timothy J.
    Levy, Donald S.
    Reshef, Avner
    Lumry, William R.
    Martinez-Saguer, Inmaculada
    Jacobs, Joshua S.
    Yang, William H.
    Ritchie, Bruce
    Aygoeren-Puersuen, Emel
    Keith, Paul K.
    Busse, Paula
    Feuersenger, Henrike
    Bica, Mihai Alexandru
    Jacobs, Iris
    Pragst, Ingo
    Magerl, Markus
    LANCET HAEMATOLOGY, 2024, 11 (06): : e436 - e447
  • [25] Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
    Deodhar, Atul
    Navarro-Compan, Victoria
    Poddubnyy, Denis
    Gensler, Lianne S.
    Ramiro, Sofia
    Tomita, Tetsuya
    Marzo-Ortega, Helena
    Fleurinck, Carmen
    Vaux, Thomas
    Massow, Ute
    de Peyrecave, Natasha
    van der Heijde, Desiree
    Baraliakos, Xenofon
    RMD OPEN, 2025, 11 (01):
  • [26] A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults with ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE): An Interim Analysis
    Sabbagh, Yves
    Shenouda, Magdy
    Taubel, Jorg
    Lebwohl, Mark
    Gunter, Kurt
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 72 - 72
  • [27] Efficacy and Safety of Upadacitinib After 3 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Label Extension Study (U-ACTIVATE)
    Panaccione, Remo
    Higgins, Peter
    Nakase, Hiroshi
    Glover, Sarah C.
    Danese, Silvio
    Colombel, Jean-Frederic
    Eccleston, Jason
    Kujawski, Michelle
    Remple, Valencia
    Yao, Xuan
    Suravaram, Smitha
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10): : S1061 - S1062
  • [28] Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: interim long-term data from the phase 3 open-label extension study (U-ACTIVATE)
    Panaccione, R.
    Lichtenstein, G.
    Colombel, J. F.
    Nakase, H.
    Yao, X.
    Klaff, J.
    Kujawski, M.
    Rizzo, L.
    Suravaram, S.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i80 - i82
  • [29] RESULTS OF A 52 WEEK OPEN-LABEL PHASE 2B STUDY TO ASSESS LONG-TERM SAFETY, IMMUNOGENICITY AND LDL-C EFFICACY OF MONTHLY DOSING WITH LIB003 A NOVEL ANTI-PCSK9 RECOMBINANT FUSION PROTEIN
    Turner, T. A.
    Butcher, B.
    Mangu, P.
    Kereiakes, D.
    Fu, R.
    Bakker-Arkema, R.
    Stein, E. A.
    ATHEROSCLEROSIS, 2020, 315 : E9 - E9
123